A study published in Clinical and Translational Science examined how the risks of disease flare and joint damage change over time when patients with well-controlled RA taper or discontinue their medication. The researchers analyzed 27 publications representing 23 randomly assigned controlled trials, involving a total of 5,262 patients. The studies compared continued treatment with strategies that reduced DMARD doses, gradually lengthened dosing intervals, or discontinued medication altogether. The analysis also examined whether outcomes differed according to the type of medication and the length of follow-up.
The findings showed that reducing treatment increased the risk of disease flare. Across the studies, DMARD tapering was associated with a 56% higher relative risk of flare compared with continuing treatment (risk ratio [RR] 1.56, 95% confidence interval [CI] 1.26–1.98). The increase was largely driven by biologic DMARDs, with the clearest difference emerging during the first nine months after tapering began. During this period, the relative risk of flare was 1.61 (95% CI 1.13–2.31). The difference was not statistically significant at longer follow-up, although this does not establish that the long-term risks disappear.
Completely stopping treatment was associated with a greater and more persistent risk. DMARD withdrawal increased the relative risk of flare by 123% compared with continued treatment (RR 2.23, 95% CI 1.83–2.94). This pattern was particularly apparent with biologic DMARDs, for which the increased risk persisted across short-, intermediate-, and long-term follow-up periods. These results suggest that gradually reducing medication and stopping it entirely should not be considered equivalent strategies.
The researchers also examined radiographic progression, which refers to structural joint damage visible on imaging. Both tapering and withdrawal were associated with evidence of increased progression during intermediate- and longer-term follow-up, although the evidence for tapering was weaker. This finding is important because a patient may experience renewed inflammation and accumulating joint damage even if symptoms initially remain manageable.
One of the more striking findings was that reducing or stopping DMARDs did not produce a clear reduction in adverse events. Although minimizing medication exposure is often considered a way to improve safety, the analysis did not demonstrate that either strategy reliably reduced adverse events during the periods studied. The potential benefits of lowering treatment therefore need to be weighed against the risk of losing disease control.
There are limitations to consider. The included trials differed in medication types, tapering schedules, definitions of disease flare, and follow-up durations. Rare adverse events and long-term outcomes were also difficult to assess consistently. Consequently, the findings do not mean that every patient will experience a flare after reducing treatment, nor do they establish that tapering is never appropriate.
Overall, the review supports a cautious, individualized approach to DMARD de-escalation. For patients with sustained disease control who wish to reduce treatment, decisions should be made collaboratively with their rheumatologist, with careful monitoring and a plan for responding to recurrent inflammation. Complete withdrawal, in particular, carries a substantial risk of flare and should generally be avoided when continued treatment remains appropriate.